The purpose of this post is to demonstrate the utility of Biovista’s Vizit to review and explore specific biomedical domains. In the current example, Vizit is used to identify genes, cell types and microbiome organisms related to Regulatory T cells (Tregs) in the setting of cancer immunotherapy. These entities may have an impact on the … Read More
CHARLOTTESVILLE, Virginia, December 2, 2015 /PRNewswire/ — Biovista announced today that it has entered into a drug repositioning collaboration with Astellas Pharma Inc. The collaboration is focused on identifying new indications for a number of undisclosed Astellas compounds using Biovista’s Clinical Outcome Search Space (COSS) technology. “We look forward to working with the Drug Repurposing … Read More
Charlottesville, June 10, 2014 Biovista announces online environment for in-context selling of life science products Biovista announced today the availability of its viz.it solution. Aimed at reagent and life-sciences product companies viz.it integrates seamlessly with customer web sites and their online product catalogs and payment systems. Short for “visualize it”, viz.it lets scientists/researchers browse through … Read More
Article by Marie Powers in BioWorld; Monday, June 10, 2013 Article summary: Chronic fatigue syndrome (CFS) has been at the center of a vortex of controversy since the FDA handed down a complete response letter on the Toll-like receptor 3 modulator Ampligen (rintatolimod) from Hemispherx Bioscience Inc. – the only drug in development for CFS … Read More
Presentation- CFIDS Association of America / Biovista View the joint presentation by Biovista President Dr. Aris Persidis and CFIDS’ Scientific Director, Dr. Suzanne Vernon at the 2012 Partnering for Cures conference. The collaboration between the CFIDS Association of America and Biovista leverages the accumulated knowledgebase for chronic fatigue syndrome (CFS) and Biovista’s state-of-the-art approaches to … Read More